Sightera
Antwerp, Belgium
◆ About Sightera
Belgian biotech company using AI drug discovery by learning from extreme patient biology.
◆ What sets it apart
Sightera reverses the standard target-first approach by first analyzing 'extreme' patient biology to surface therapeutic insights, then using AI to design small molecules with novel mechanisms of action.
◆ Sectors
◆ Business
ModelB2B partnership
CustomerPharmaceutical and biotechnology companies
◆ Notable
- Closed €3M pre-seed funding round in July 2026 led by Entourage Ventures, Anacura, and QBIC
- Spin-off from University of Antwerp and Antwerp University Hospital (UZA)
- Developing proprietary SPAR (Structure-Patient-Activity-Relationship) technology
- Current pipelines focused on oncology and fibrosis/regenerative medicine
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Sightera do?
Belgian biotech company using AI drug discovery by learning from extreme patient biology.
Where is Sightera based?
Sightera is based in Antwerp, Belgium.
How much has Sightera raised?
Sightera has raised $3.3M in tracked funding and is currently at the seed stage.
Who has invested in Sightera?
Investors in Sightera include Entourage Ventures, Anacura and QBIC Fund.